Meeting
2023 ASCO Genitourinary Cancers Symposium
Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.
Authors
Heba Mohamed
Abbotsford Regional Hospital and Cancer Centre, Abbotsford, BC, Canada
Heba Mohamed , Grace Kim , Corin Macphail , Ishmam Bhuiyan , Taylor Sidhu , Amir Emami , Longlong Huang , Shaun Zheng Sun , Scott Tyldesley , Jenny J. Ko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 89)
DOI
10.1200/JCO.2023.41.6_suppl.89
Abstract #
89
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2023 ASCO Genitourinary Cancers Symposium
Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC).
First Author: Praful Ravi
Poster
2019 ASCO Annual Meeting
Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis.
First Author: Catherine Handy Marshall